Drug interaction study tests cancer Drug's effect on diabetes medication

NCT ID NCT05469113

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study in 16 healthy adults looked at whether taking multiple doses of selpercatinib (a cancer drug) changes how the body processes repaglinide (a diabetes medication). Participants received both drugs in a fixed order, and researchers measured drug levels in the blood over 12 days. The goal was to gather safety and drug interaction information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selpercatinib (also known as LOXO-292) and repaglinide
What this could lead to: If successful, this study could help doctors understand how to safely combine selpercatinib with other drugs that are broken down similarly in the body.
What could go wrong: This is a small, early-stage study in healthy volunteers, not patients. It only looks at drug levels, not actual treatment effects, so results may not apply to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Celerion

Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.